Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724391 | SCV000230544 | pathogenic | not provided | 2016-10-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000527540 | SCV000649694 | pathogenic | Qualitative or quantitative defects of dysferlin | 2024-02-14 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp1478*) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (rs766016391, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with LGMD and/or proximodistal myopathy (PMID: 17698709, 25868377). ClinVar contains an entry for this variant (Variation ID: 197433). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000724391 | SCV002021855 | pathogenic | not provided | 2023-12-13 | criteria provided, single submitter | clinical testing | |
3billion, |
RCV000178461 | SCV002318690 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2022-03-22 | criteria provided, single submitter | clinical testing | Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000197433, PMID:25868377). The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency:0.0000040). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
Athena Diagnostics | RCV000724391 | SCV002770745 | pathogenic | not provided | 2022-05-12 | criteria provided, single submitter | clinical testing | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been seen in individuals with limb-girdle muscular dystrophy or myopathy. |
Fulgent Genetics, |
RCV002485170 | SCV002782999 | pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset | 2022-03-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003468866 | SCV004194160 | pathogenic | Miyoshi muscular dystrophy 1 | 2024-02-26 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000724391 | SCV005413458 | pathogenic | not provided | 2024-01-11 | criteria provided, single submitter | clinical testing | PP4, PM2_moderate, PM3, PVS1 |
Counsyl | RCV000178461 | SCV000795634 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-11-10 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000178461 | SCV001452776 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-09-16 | no assertion criteria provided | clinical testing |